Yan Tan
谭验
Yan Tan is a Chinese biotech founder who co-founded and serves as CEO of Unknown (未知君), a microbiome drug development company applying AI to gut-microorganism therapeutics . He holds a PhD and founded the company in the late 2010s, with Unknown raising tens of millions in Series B+ funding by late 2020 and nearly $100 million in a Series B round by late 2021 to advance its clinical trials and AI×BT platform . At the time of the 2021 funding, Yan Tan described the company's progress as having moved self-developed drugs into registrational clinical trials while rapidly iterating its platform technology .
AI-generated — may contain errors, please verify.
Coverage
Golden Skies, Orange Leaves, Good News with Autumn | Z News
The autumn air is crisp and clear.
The unthinkable is precisely what can be thought. | 5Y News Monthly
The big news from last month.
Multiple Innovative Companies Gain Global Recognition, Breakthroughs Achieved in Computational Biology, LiDAR, and Other Fields | Rongbao · July
Major events in July.
Robots, AI, and Simulation Technologies Accelerate Industrial Adoption | Rongbao · June
Technology drives industrial transformation.
July: Seeking Vast Possibilities | 5Y News Monthly
The big news from last month.
5Y Capital and Multiple Portfolio Founders Win Multiple Awards from 36Kr and *Fortune* Magazine | 5Y News
5Y Capital continues to seek out, support, and stand by the rarest founders.
Unknown Closes Nearly $100 Million in Series B Funding, Launches AI×BT Strategy
Focused on gut microbiome AI-driven drug discovery, with self-developed drug candidates already in registrational clinical trials.
5Y News | AI Microbiome Drug Developer "Unknown" Closes Nearly $100 Million Series B Financing
Launching a new AI×BT strategy.
When a group of genuine, smart, and interesting young tech people live together for five days and four nights | 3Sigma Bootcamp documentary
The few who exist beyond 3Sigma — kindred spirits on the entrepreneurial road.
5Y Talk | Next-Gen Computing + Experimentation: The Birth of New Application Categories
Technology, Industry, and the Future.
5Y News｜Unknown Closes Tens of Millions of Dollars in Series B+ Funding to Advance Microbiome Drug Clinical Trials
Leading domestic microbiome therapeutics company Unknown has recently completed a tens-of-millions-of-dollars Series B+ funding round, with continued backing from 5Y Capital.
China's First AI Microbiome Drug Company "Unknown" Raises Nearly $10 Million in Funding
Leveraging AI and bioengineering technologies to deliver precision management of gut health for Chinese consumers.
